- Study Says Most Parents Don’t Use Car Seats In Ride Share Vehicles Like Uber
- This 12-Year-Old Boy Is A Sophomore Aerospace Engineering Major!
- Fire Safety Experts Warn Of Hand Sanitizer Danger After A Mom and Kids Escape House Fire
- Recall Alert: Peaches May Be The Cause Of Salmonella Outbreak, 68 People Ill
- Summer Vacation In The Days Of COVID: Tips To Stay Safe
- How To Safely Grocery Shop During The Coronavirus Pandemic
- Michigan Teen With Vape-Related Illness Undergoes Double Lung Transplant
- Teen Kicks Off Anti-Vaping Campaign From Hospital Bed
- Teenager Receives Life Sentence For Strangling Sister To Death Over A Wi-Fi Password
- Toddler Falls To Death From 11th Deck of Cruise Ship
RECALL ALERT: Faulty EpiPens
A recall has been issued for affected EpiPens – as they can fail to activate in an emergency.
The makers of EpiPen, Mylan, have issued the recall due to reports of EpiPens failing to activate.
The company recalled 81,000 EpiPens over the world, including in Europe, Australia, New Zealand, and Japan. Now, the recall has spread to 13 lots of the EpiPen and EpiPen Jr. Auto-Injector, following 2 reports that the life-saving pen did not activate when needed.
Considering that a dose of epinephrine is administered immediately after an allergic reaction takes place – this is really scary. It can mean the difference between life and death!
It’s estimated that 1 in 13 kids has a food allergy in the U.S, so it’s important to note that this recall affects both EpiPens parents keep on hand at home in case of an allergic reaction, but it also affects those they supply to schools and daycares.
Visit Mylan’s website to see full details about the recall, including exactly which products are affected, their lot numbers, and expiration dates. The number of pens included in the recall is small, and the generic form of the medication is safe.
According to a statement by the company, “Mylan is committed to replacing recalled devices at no cost and Mylan would like to reassure patients that there will be no additional replacement-related financial burden to them as a result of this recall.”
0 comments